Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Brand Name : LYT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2023
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYT-300 is a clinical therapeutic candidate that is in development as a potenƟal treatment for a range of neurological and neuropsychological condions. Developed using PureTech's Glyph™ technology plaƞorm, LYT-300 is an oral prodrug of natural allopr...
Brand Name : LYT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2022
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYT-300 is an oral prodrug of natural allopregnanolone candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions. Developed using PureTech's Glyph technology platform.
Brand Name : LYT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2022
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYT-300 (Oral Allopregnanolone), is the first candidate from the GlyphTM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech’s pipeline.
Brand Name : LYT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2021
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Allopregnanolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Asarina Pharma Reports Topline Results from Phase Iib Study in PMDD
Details : Substantial reduction in PMDD symptoms was achieved across the patient population, but, in comparison to placebo, primary and secondary endpoints were not statistically significant.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 21, 2020
Lead Product(s) : Allopregnanolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?